To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

Substantial anti-resorptive effects achieved with 1mg and 2.5mg doses of zoledronate

Download
Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Author Verified
Ace Report Cover
July 2013

Substantial anti-resorptive effects achieved with 1mg and 2.5mg doses of zoledronate

Vol: 2| Issue: 6| Number:8| ISSN#: 2564-2537
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:N/A

Low-dose zoledronate in osteopenic postmenopausal women: a randomized controlled trial

J Clin Endocrinol Metab. 2012 Jan;97(1):286-92. doi: 10.1210/jc.2011-2081. Epub 2011 Nov 9

Contributing Authors:
A Grey M Bolland S Wong A Horne G Gamble IR Reid

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

One hundred and eighty postmenopausal women with osteopenia were randomized into 4 groups and received either a single IV infusion of 5mg, 2.5mg, 1mg, or placebo zoledronate to determine the antiresorptive properties of each dose. Bone mineral density and bone turnover were assessed 12 months after administration. The results indicated that the lower doses produced considerable antiresorptive effe...

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.

Learn about our AI Driven
High Impact Search Feature

High Impact Icon

The OE High Impact metric uses AI to determine the impact a study will have by considering the content of the article itself. Built using the latest advances of natural language processing techniques. OE High Impact predicts an article’s future number of citations than impact factor alone.

Continue